

**EXHIBIT I****McDermott  
Will & Emery**

Boston Brussels Chicago Düsseldorf London Los Angeles Miami Munich  
New York Orange County Rome San Diego Silicon Valley Washington, D.C.

William G. Gaede III  
Attorney at Law  
wgaede@mwe.com  
650.813.5035

March 27, 2007

**VIA FACSIMILE AND E-MAIL**


Hank Heckel, Esq.  
Kaye Scholer LLP  
425 Park Avenue  
New York, NY 10022-3598

**Re: *Amgen Inc. v. F. Hoffmann-La Roche Ltd., et al.***  
**Case No. 05 Civ. 12237 WGY**

Dear Hank:

This letter is in response to your letter of March 26, 2007 to Adam Bier regarding a December 20, 1989 memorandum from Vapnek to various individuals. Our review indicates that the document was erroneously claimed as privileged. A copy of the document is enclosed with this letter. We will provide a Bates-labeled copy of the document later today or tomorrow.

Very truly yours,



William G. Gaede, III

Enclosure

cc: Mike Gottfried, Esq.  
Krista Carter, Esq.  
Sandip H. Patel, Esq.

**AMGEN**

Date: December 20, 1989

To: J. Browne  
T. Byrne  
J. Egrie  
S. Elliott  
T. Strickland

From: Daniel Vapnek

Congratulations on being named to the new EPO team which will deal specifically with developing new EPO products which do not fall within Claim 1 of the 195 patent.

Joan Egrie and Tom Strickland will head the team and I will also participate. The first team meeting will be held the week of January 3rd. Please come to the meeting prepared to discuss your best ideas.

P.S. Claim 1 of the 195 patent reads:  
Homogeneous erythropoietin characterized by a molecular weight of about 34,000 daltons on SDS PAGE, movement as a single peak on reverse phase high performance liquid chromatography and a specific activity of at least 160,000 IU per absorbance unit at 280 nanometers.

DV/sa

AM 28 000556  
**CONFIDENTIAL**